{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+human+hyaluronidase",
    "query": {
      "intervention": "recombinant human hyaluronidase"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 123,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+human+hyaluronidase&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T06:36:54.732Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01170897",
      "title": "Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-07",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-29",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Encinitas, California • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170897"
    },
    {
      "nct_id": "NCT06046287",
      "title": "Daratumumab for Polyneuropathy Associated With MGUS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Neuropathy",
        "Monoclonal Gammopathy of Undetermined Significance"
      ],
      "interventions": [
        {
          "name": "Daratumumab and hyaluronidase-fihj",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-09-26",
      "completion_date": "2025-09-26",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06046287"
    },
    {
      "nct_id": "NCT01139294",
      "title": "Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dehydration",
        "Cardiac Output",
        "Pediatrics"
      ],
      "interventions": [
        {
          "name": "Hylenex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "2 Months to 3 Years"
      },
      "enrollment_count": 17,
      "start_date": "2010-02",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2018-02-01",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01139294"
    },
    {
      "nct_id": "NCT05511428",
      "title": "Home Based Daratumumab Administration for Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab and Hyaluronidase-fihj",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-11-08",
      "completion_date": "2024-05-22",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05511428"
    },
    {
      "nct_id": "NCT01987609",
      "title": "Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Hylenex",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tissa Hata, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 7,
      "start_date": "2015-07",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2019-01-04",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01987609"
    },
    {
      "nct_id": "NCT03634332",
      "title": "Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Cancer",
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pancreatic Cancer Research Team",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2019-05-01",
      "completion_date": "2021-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 5,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • New Brunswick, New Jersey + 2 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03634332"
    },
    {
      "nct_id": "NCT01839487",
      "title": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 279,
      "start_date": "2013-05-14",
      "completion_date": "2018-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01839487"
    },
    {
      "nct_id": "NCT00782106",
      "title": "Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "Recombinant human hyaluronidase + immune globulin intravenous",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2006-12-04",
      "completion_date": "2007-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 3,
      "location_summary": "Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782106"
    },
    {
      "nct_id": "NCT07485647",
      "title": "Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab and Recombinant Human Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eden Biltibo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-04-20",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07485647"
    },
    {
      "nct_id": "NCT03972306",
      "title": "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "rHuPH20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 134,
      "start_date": "2019-08-12",
      "completion_date": "2025-06-03",
      "has_results": false,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-09-24T06:36:54.732Z",
      "location_count": 18,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Alexandria",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972306"
    }
  ]
}